Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up

Background: Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at stages 3–5, analyzed the impact of statin and other antihyperglycemic interventi...

Full description

Saved in:
Bibliographic Details
Main Authors: Ammar Abdulrahman Jairoun, Chong Chee Ping, Baharudin Ibrahim, Dina Farhan Al Jawamis, Asma Khaled Al Jaberi, Tasnim Dawoud, Khuloud Jamal Mohammed, Faris El-Dahiyat, Moyad Shahwan
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Pharmaceutical Policy and Practice
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/20523211.2024.2414293
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846114547659702272
author Ammar Abdulrahman Jairoun
Chong Chee Ping
Baharudin Ibrahim
Dina Farhan Al Jawamis
Asma Khaled Al Jaberi
Tasnim Dawoud
Khuloud Jamal Mohammed
Faris El-Dahiyat
Moyad Shahwan
author_facet Ammar Abdulrahman Jairoun
Chong Chee Ping
Baharudin Ibrahim
Dina Farhan Al Jawamis
Asma Khaled Al Jaberi
Tasnim Dawoud
Khuloud Jamal Mohammed
Faris El-Dahiyat
Moyad Shahwan
author_sort Ammar Abdulrahman Jairoun
collection DOAJ
description Background: Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at stages 3–5, analyzed the impact of statin and other antihyperglycemic interventions, on the CKD progression in individuals with T2DM.Methods: This was a single-center retrospective cohort study based on data derived from electronic medical records (EMR) of UAE populations with diabetes mellitus, registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between January 2011 and December 2021. T2DM patients aged ≥ 18 years who had serum HbA1c level ≥ 6.5% and using one of the statin therapies were inclusion criteria. Patients with T1DM, who had undergone permanent renal replacement therapy, with under 1 year of follow-up and missing or incomplete data were excluded from the study. The collected data encompassed socio-demographics, detailed medical history, anthropometric measurements, laboratory analyses, clinical parameters, disease characteristics, and medications.Results: Our study included a cohort of 1,003 individuals. We observed 388 subjects developed CKD stages 3–5 across an average monitoring duration of 11.7 years. This resulted in a cumulative incidence of 38.7%, translating to an incidence rate of 38 cases per 1000 person-years. There was a statistically significant difference in the cumulative incidence of CKD stages 3 ± 5 according to statin therapy (P = 0.047). High intensity statin users are more likely to develop a CKD stage 3–5 compared to low/moderate intensity users and to no statin users respectively (44.3% vs 37.9%), (44.3% vs 30.9%). Conversely, the use of Biguanides was associated with a decreased probability of CKD progression (37.9% vs. 52.8%; P = 0.001), whereas Insulin users demonstrated a heightened risk (54.2% vs. 34.1%; P < 0.001).Conclusion: The findings emphasise the pivotal role of personalised treatment strategies, particularly concerning statin therapy and other medications, in populations at high risk.
format Article
id doaj-art-c6733e268db84362a3b3aad2ae20c0ae
institution Kabale University
issn 2052-3211
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Journal of Pharmaceutical Policy and Practice
spelling doaj-art-c6733e268db84362a3b3aad2ae20c0ae2024-12-20T11:09:07ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112025-12-0118110.1080/20523211.2024.2414293Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-upAmmar Abdulrahman Jairoun0Chong Chee Ping1Baharudin Ibrahim2Dina Farhan Al Jawamis3Asma Khaled Al Jaberi4Tasnim Dawoud5Khuloud Jamal Mohammed6Faris El-Dahiyat7Moyad Shahwan8Discipline of clinical pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM), Pulau Pinang, MalaysiaDiscipline of clinical pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM), Pulau Pinang, MalaysiaFaculty of Pharmacy, Universiti Malaya, Kuala Lumpur, MalaysiaPharmacy Department, Tawam Hospital, SEHA, Al Ain, United Arab EmiratesEndocrinology Department, SEHA, Al Ain, United Arab EmiratesPharmacy Department, Tawam Hospital, SEHA, Al Ain, United Arab EmiratesPharmacy Department, Tawam Hospital, SEHA, Al Ain, United Arab EmiratesClinical Pharmacy Program, College of Pharmacy, Al Ain University, Al Ain, United Arab EmiratesCollege of Pharmacy and Health Sciences, Ajman University, Ajman, UAE.Background: Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at stages 3–5, analyzed the impact of statin and other antihyperglycemic interventions, on the CKD progression in individuals with T2DM.Methods: This was a single-center retrospective cohort study based on data derived from electronic medical records (EMR) of UAE populations with diabetes mellitus, registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between January 2011 and December 2021. T2DM patients aged ≥ 18 years who had serum HbA1c level ≥ 6.5% and using one of the statin therapies were inclusion criteria. Patients with T1DM, who had undergone permanent renal replacement therapy, with under 1 year of follow-up and missing or incomplete data were excluded from the study. The collected data encompassed socio-demographics, detailed medical history, anthropometric measurements, laboratory analyses, clinical parameters, disease characteristics, and medications.Results: Our study included a cohort of 1,003 individuals. We observed 388 subjects developed CKD stages 3–5 across an average monitoring duration of 11.7 years. This resulted in a cumulative incidence of 38.7%, translating to an incidence rate of 38 cases per 1000 person-years. There was a statistically significant difference in the cumulative incidence of CKD stages 3 ± 5 according to statin therapy (P = 0.047). High intensity statin users are more likely to develop a CKD stage 3–5 compared to low/moderate intensity users and to no statin users respectively (44.3% vs 37.9%), (44.3% vs 30.9%). Conversely, the use of Biguanides was associated with a decreased probability of CKD progression (37.9% vs. 52.8%; P = 0.001), whereas Insulin users demonstrated a heightened risk (54.2% vs. 34.1%; P < 0.001).Conclusion: The findings emphasise the pivotal role of personalised treatment strategies, particularly concerning statin therapy and other medications, in populations at high risk.https://www.tandfonline.com/doi/10.1080/20523211.2024.2414293StatinType 2 diabetes mellituscohort studymetformindiabetic nephropathychronic kidney disease
spellingShingle Ammar Abdulrahman Jairoun
Chong Chee Ping
Baharudin Ibrahim
Dina Farhan Al Jawamis
Asma Khaled Al Jaberi
Tasnim Dawoud
Khuloud Jamal Mohammed
Faris El-Dahiyat
Moyad Shahwan
Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up
Journal of Pharmaceutical Policy and Practice
Statin
Type 2 diabetes mellitus
cohort study
metformin
diabetic nephropathy
chronic kidney disease
title Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up
title_full Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up
title_fullStr Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up
title_full_unstemmed Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up
title_short Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up
title_sort effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus a retrospective cohort study with a 12 year follow up
topic Statin
Type 2 diabetes mellitus
cohort study
metformin
diabetic nephropathy
chronic kidney disease
url https://www.tandfonline.com/doi/10.1080/20523211.2024.2414293
work_keys_str_mv AT ammarabdulrahmanjairoun effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT chongcheeping effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT baharudinibrahim effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT dinafarhanaljawamis effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT asmakhaledaljaberi effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT tasnimdawoud effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT khuloudjamalmohammed effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT fariseldahiyat effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup
AT moyadshahwan effectofstatinsandantihyperglycemicsonchronickidneydiseaseinpatientswithtype2diabetesmellitusaretrospectivecohortstudywitha12yearfollowup